Phase 2 Interstitial Lung Disease Trial, Not Yet Recruiting NCT07019090 Sponsor: Haisco Pharmaceutical Group Co., Ltd. Condition: Interstitial Lung Disease
Back to Interstitial Lung Disease

Phase 2 Interstitial Lung Disease Trial, Not Yet Recruiting

NCT07019090
Not Yet Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have a lung condition called IPF (idiopathic pulmonary fibrosis) and previously completed a full course of treatment with a drug called HSK44459 in an earlier study, without stopping the treatment early for permanent reasons
  • The medical team running the trial has assessed that the potential benefits of continuing HSK44459 treatment outweigh the risks for you personally

Who may not be able to join:

  • You are planning to have a lung transplant
  • You have a low body weight (BMI under 18.5) and experienced unexplained weight loss of more than 10% during the previous study
  • You have been diagnosed with any form of cancer in the last 5 years before the screening appointment
  • You have a history of depression or an anxiety disorder

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 18036618841

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 2
Sponsor
Haisco Pharmaceutical Group Co., Ltd.
Registry
ClinicalTrials.gov
Start date
27 June 2025
Est. completion
31 October 2026

Primary endpoints

The incidence and severity of adverse events during the study period

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov